BioSpace News Archive

Immunovia announces the appointment of Norma Alonzo Palma, PhD as Vice President of Clinical and Medical Affairs.

Boston Scientific Corporation (NYSE: BSX) announced it has received U.S. Food and Drug Administration (FDA) approval for the FARAPULSE™ Pulsed Field Ablation (PFA) System.

Thermo Fisher Scientific Inc., the world leader in serving science, reported its financial results for the fourth quarter and full year ended December 31, 2023.

BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Duality Biologics (Suzhou) Co., Ltd. (“DualityBio”) today announced that the U.S. Food and Drug Administration (“FDA”) granted Fast Track designation for BNT325/DB-1305 for the treatment of patients with platinum-resistant ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer who have received one to three prior systemic treatment regimens.

InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Carotid Stent System (EPS) for the prevention of stroke, today announced that it has received CE Mark recertification under the European Union’s new Medical Device Regulation (MDR) regulatory framework.

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) today announced that George Elston, Executive Vice President and Chief Financial Officer of EyePoint Pharmaceuticals, will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Wednesday, February 7, 2024 at 12:30 p.m. ET.

Tango Therapeutics, Inc. announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference on Wednesday, February 7, 2024 at 11:30 AM EST.

Monte Rosa Therapeutics announced that management will participate in the following investor conferences.

SpringWorks Therapeutics, Inc. (Nasdaq: SWTX) today announced that management will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference, taking place in New York, New York on Thursday, February 8, 2024 at 2:00 p.m. ET.

Trinity Biotech plc (Nasdaq: TRIB) today announced the Company’s results for the quarter ended September 30, 2023.